Drugs in ATC Class A07AA

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A07 - ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

Up to A07A - INTESTINAL ANTIINFECTIVES

Drugs in ATC Class: A07AA - Antibiotics

Tradename	Generic Name
NEO-CORT-DOME	acetic acid, glacial; hydrocortisone; neomycin sulfate
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate
CORTISPORIN	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate

ATC Class A07AA (Antibiotics) Market Dynamics and Patent Landscape

Last updated: April 24, 2026

What does ATC class A07AA cover, and where does revenue concentrate?

ATC class A07AA is Antibiotics in the Alimentary tract and metabolism category. The class is used for systemic or locally acting antibiotics within gastrointestinal indications, including agents used for bowel-related infections and related microbiome-modulating antibiotic therapies.

Market concentration tends to follow two patterns:

1. Established agents dominate share where patents are expired or close to expiry and generics are entrenched.
2. Specialty and niche anti-infectives sustain premium pricing in populations where antibiotic selection is constrained by resistance, safety, and formulary access.

For the patent landscape, the practical reality is that A07AA value pools generally track:

• Originator antibiotics with long IP tails (composition-of-matter plus polymorph/process),
• Second-generation reformulations (new salts, crystal forms, dosage forms), and
• Antibiotics with expanded label tied to new clinical cohorts or endpoints.

What are the market dynamics that shape A07AA competition?

Key dynamics affecting antibiotics in A07AA-style GI use cases:

1) Resistance pressure changes prescribing and label breadth

• Antibiotics in GI settings face shifting resistance patterns across geographies.
• Resistance management pushes payers toward therapies with clearer microbiological rationale and stewardship alignment.

2) Formularies and stewardship drive volume volatility

• Antibiotics can lose access when stewardship programs tighten.
• Reimbursement and access decisions often follow guideline updates and payer antibiogram models.

3) Safety tolerance is decisive for GI populations

• GI tolerability and withdrawal rates affect real-world use.
• Short-course regimens with predictable exposure profiles tend to keep competitive advantage.

4) Patent cliffs and generics compress pricing

• Once core composition or key process IP expires, margin typically collapses within the year subsequent to generic launches.

5) Differentiation shifts from molecule to IP bundling

• Companies increasingly rely on:
  • New crystal forms and solid-state specs
  • Process improvements
  • Combination regimens or sequencing claims
  • Device and administration claims only when legally and technically defensible

How does the patent landscape typically look for A07AA antibiotics?

Patent coverage for antibiotics used in GI indications commonly splits into four buckets:

A) Composition-of-matter (core)

• Breadth varies widely.
• For established antibiotics, composition IP is frequently expired, leaving only:
  • Second-generation forms (salt/polymorph)
  • Process patents
  • Use patents

B) Solid-state and form patents (crystal/polymorph)

• These are a common source of incremental IP around mature antibiotics.
• Even when the active is old, new solid-state forms can create enforceable gaps.

C) Process patents

• Manufacturing improvements can survive longer than composition IP if they are novel and non-obvious.
• These are often the last line of IP defense against generic entry.

D) Method-of-use and regimen patents

• Use claims may cover:
  • Specific GI infections
  • Specific patient groups
  • Specific dosing sequences or duration windows

Practical implication: For A07AA competitors, enforceability often rests on whether the generic challenger can design around a form or method claim, not whether it can avoid a generic version of the parent molecule.

Which patent and market forces dominate near-term outcomes?

Near-term outcomes for A07AA antibiotics generally hinge on:

• Whether the originator has unexpired solid-state or process IP
• Whether generics launched at risk have settled via licensing or appear with design-around
• Whether new evidence supports expanded use that triggers new method claims
• Whether stewards restrict the class, reducing the size of “treatable” populations

What does the competitive patent model imply for R&D and licensing?

For entrants and investors, the A07AA patent landscape usually rewards one of two strategies:

1. Secure enforceable incremental IP
   • Target solid-state forms, dosing regimens, or specific use claims with defensible novelty.
2. License or acquire a molecule with active IP tail
   • Focus on remaining jurisdictions where process/form/use patents still block generics.

Where are the likely patent “pressure points” for generic challenge?

The generic attack vector typically depends on what remains in force:

• If only process claims remain: generics can pursue different manufacturing routes.
• If only form claims remain: generics can attempt to supply alternative polymorphs or salts.
• If use claims remain: generics can omit the labeled method from marketing, but enforcement depends on claim scope and evidence of induced infringement.

This drives how originators draft claims and how entrants design freedom-to-operate strategies.

What is the actionable investment view of A07AA dynamics?

Investment lens:

• A07AA value shifts most quickly when a key molecule moves through:
  • Patent expiry
  • Generic launch
  • Stewardship guideline change
  • Resistance-driven guideline re-ranking

Investment lens for patent risk:

• The highest-risk period for originator revenue is the 12 to 24 months around the first meaningful generic filing or launch, when settlements and at-risk launches shape future earning power.

Key Takeaways

• A07AA (Antibiotics) sits in a GI-relevant antibiotics space where prescribing is heavily shaped by stewardship and resistance.
• Market share and margins compress rapidly once core composition IP expires, unless originators retain enforceable solid-state (salt/polymorph), process, or method-of-use IP.
• Patent lifecycles in A07AA typically end with narrow but enforceable incremental patents that determine whether generics can design around.
• For R&D and licensing, the highest-value target is not simply a new molecule, but a molecule with a defensible IP tail that blocks generic substitution.

FAQs

1. What types of patents most often extend exclusivity for A07AA antibiotics?
   Solid-state (salts/polymorphs), manufacturing processes, and method-of-use/regimen patents.

2. Why does antibiotic prescribing in GI indications move with resistance trends?
   Resistance patterns change guideline recommendations and insurer stewardship protocols.

3. What triggers the fastest revenue compression in this class?
   The transition from originator exclusivity to first generic launch, especially where no strong form or process IP remains.

4. How do generics typically design around remaining A07AA patents?
   By changing manufacturing routes (process) or selecting alternative solid forms (salt/polymorph), and by avoiding the claimed method-of-use.

5. What is the most investable IP posture for a new entrant in A07AA?
   A molecule plus incremental IP that blocks generic entry in core jurisdictions, not just a novel active ingredient.

---

References

[1] World Health Organization. ATC Classification. WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc/ (accessed 2026-04-24)